Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.3K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.3K
Drug Classes and Categories01:25

Drug Classes and Categories

3.1K
Drugs can be classified according to their chemical composition or their intended therapeutic application. For instance, anti-infective agents that possess the ability to eliminate pathogens or suppress their growth and reproduction can be grouped based on the organisms they target or their chemical structure. Furthermore, drugs can be divided into prescription, nonprescription, or controlled substances. Prescription medications, such as antibiotics, require oversight from a licensed healthcare...
3.1K
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

1.9K
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
1.9K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

1.8K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.8K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

3.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatotoxicity With Elevated Bilirubin Secondary to Prophylactic Doses of Unfractionated Heparin: A Case Report and Review of Heparin-Induced Hepatotoxicity.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Techniciansยท2021
Same author

Promising Multiple Sclerosis Agents In Late-Stage Development.

P & T : a peer-reviewed journal for formulary managementยท2018
Same author

Emerging Therapies for Patients With Difficult-to-Treat Migraine.

P & T : a peer-reviewed journal for formulary managementยท2018
Same author

Risk Reduction to Disease Management: Clinical Pharmacists as Cardiovascular Care Providers.

Current problems in cardiologyยท2018
Same author

Targeting Remission in Moderate-to-Severe Crohn's Disease.

P & T : a peer-reviewed journal for formulary managementยท2018
Same author

The role of the pharmacist in hypertension management.

Current opinion in cardiologyยท2018

Related Experiment Video

Updated: Feb 6, 2026

Ultrasound Cyclo Plasty in Eyes with Glaucoma
05:05

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

12.7K

Old and New Drug Classes Expanding To Include Glaucoma Treatments.

Troy Kish

    P & T : a Peer-Reviewed Journal for Formulary Management
    |August 14, 2018
    PubMed
    Summary

    Patient adherence challenges in glaucoma management are driving innovation. New long-acting drug formulations and novel therapeutic classes, like guanylate cyclase activators, are under development.

    Area of Science:

    • Ophthalmology
    • Pharmacology

    Background:

    • Poor patient adherence is a significant challenge in managing glaucoma.
    • This necessitates the development of improved treatment strategies.

    Purpose of the Study:

    • To explore emerging therapeutic approaches for glaucoma management.
    • To highlight advancements addressing patient adherence issues.

    Main Methods:

    • Review of current research and development in glaucoma pharmacotherapy.
    • Identification of novel drug formulations and therapeutic classes.

    Main Results:

    • Several long-acting formulations of existing glaucoma medications are in early development.
    • New therapeutic classes, including guanylate cyclase activators, are being investigated.

    More Related Videos

    Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
    09:52

    Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

    Published on: March 16, 2018

    10.0K
    Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
    07:11

    Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

    Published on: May 25, 2020

    6.9K

    Related Experiment Videos

    Last Updated: Feb 6, 2026

    Ultrasound Cyclo Plasty in Eyes with Glaucoma
    05:05

    Ultrasound Cyclo Plasty in Eyes with Glaucoma

    Published on: January 26, 2018

    12.7K
    Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
    09:52

    Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

    Published on: March 16, 2018

    10.0K
    Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
    07:11

    Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

    Published on: May 25, 2020

    6.9K

    Conclusions:

    • The field is actively pursuing innovative solutions to enhance glaucoma treatment adherence.
    • These advancements promise improved patient outcomes in glaucoma care.